L 653180

Drug Profile

L 653180

Latest Information Update: 30 Aug 1995

Price : $50

At a glance

  • Originator Merck & Co
  • Class Antivirals; Nucleosides; Small molecules
  • Mechanism of Action Thymidine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Herpes simplex virus infections

Most Recent Events

  • 30 Aug 1995 New profile
  • 20 Mar 1995 No-Development-Reported for Herpes simplex virus infections in USA (Unknown route)
  • 10 Oct 1994 Preclinical development for Herpes simplex virus infections in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top